Name: EGCG ((-)-Epigallocatechin Gallate)
Brand: Selleck Chemicals
SKU: S2250
Availability: InStock
Rating: 5 (43 reviews)

Jump to

Quality Control

Batch: Purity: 99.99%

99.99

Related Targets	HDAC PARP ATM/ATR DNA-PK WRN DNA/RNA Synthesis Topoisomerase PPAR Sirtuin Casein Kinase
Other Telomerase Inhibitors	BIBR 1532 Costunolide RHPS 4 methosulfate Cycloastragenol TAC (TERT Activator-1) Cyclogalegenol Braco-19 trihydrochloride L-778123 hydrochloride Epitalon MST-312

Cell Culture, Treatment & Working Concentration

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description
SH-SY5Y cells	Function assay			Neuroprotection against beta-amyloid peptide 1-42-induced toxicity in human SH-SY5Y cells assessed as lactate dehydrogenase release, EC50=0.03987 μM
human MDA435/LCC6MDR cells	Function assay	10 μM	5 days	Modulation of P-gp (unknown origin) transfected in human MDA435/LCC6MDR cells assessed as reversible of paclitaxel resistance measured as IC50 for paclitaxel at 10 uM after 5 days by CellTiter 96 Aqueous assay, IC50=0.1226 μM
Sf9 cells	Function assay			Inhibition of His6-tagged human recombinant DNMT1 expressed in insect Sf9 cells assessed as reduction in DNA methyltransferase activity using 5'-biotinylated 45-bp unmethylated or hemimethylated oligonucleotide substrates and [3H]-AdoMet by liquid scintillation counting method, IC50=0.5 μM
human U937 cells	Function assay			Inhibition of telomerase in human U937 cells, IC50=1 μM
human HeLa cells	Function assay			Inhibition of telomerase in human HeLa cells using 5'-AAT CCG TCG AGC AGA GTT-3' as substrate incubated for 15 mins prior to extension reaction followed by compound washout by spin-telomeric repeat amplification protocol, IC50=1.08 μM
CHO cells	Cytotoxic assay		48 h	Cytotoxicity against CHO cells expressing OATP1B3 haplotype 1 after 48 hrs by fluorescence based CellTiter-Glo assay, IC50=3.2 μM
MDCK cells	Function assay		4 days	Antiviral activity against influenza A virus (A/swine/OH/511445/2007(H1N1)) Oh7 infected in MDCK cells assessed as inhibition of viral replication after 4 days by quantitative RT-PCR, ED50=8.3 μM
human HL60 cells	Proliferation assay		3 days	Antiproliferative activity against human HL60 cells after 3 days, IC50=9.4 μM
HSC-T6 cells	Function assay		48 h	Antifibrotic activity against rat HSC-T6 cells assessed as inhibition of proliferation after 48 hrs by BrdU incorporation assay, IC50=9.9 μM
mouse 3T3-L1 cells	Function assay			Inhibition of G6PD-mediated NADPH production in mouse 3T3-L1 cells, IC50=25 μM
mouse RAW264.7 cells	Function assay		5 days	Inhibition of RANKL-induced osteoclastogenesis in mouse RAW264.7 cells assessed as decrease in TRAP-positive multi-nucleated cells after 5 days, IC50=29.8 μM
HSC-T6 cells	Proliferation assay			Antiproliferative activity against rat HSC-T6 cells assessed as reduction in cell viability, IC50=29.8 μM
human A431 cells	Proliferation assay		48 h	Antiproliferative activity against human A431 cells overexpressing ErbB in serum-free medium assessed as cell viability after 48 hrs by WST-1 assay, EC50=38 μM
human MDA-MB-231 cells	Proliferation assay		24 h	Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay
human HepG2 cells	Function assay		24 h	Inhibition of oleic acid-induced triglyceride over-accumulation in human HepG2 cells incubated for 24 hrs relative to untreated control
human HepG2 cells	Function assay		24 h	Antioxidant activity in human HepG2 cells assessed as reduction of oleic acid-induced ROS generation incubated for 24 hrs by DHCF-DA based fluorimetric assay relative to untreated control
human Caco-2 cells	Growth inhibition assay	25 μM	6 days	Growth inhibition of human Caco-2 cells at 25 uM after 6 days
mouse 3T3 cells	Function assay	1-20 μM	12 h	Antimigratory activity against Swiss albino mouse 3T3 cells assessed as increase of cell numbers at 1 to 20 uM after 12 hrs by by scratch-wound assay
human MDA-MB-231 cells	Proliferation assay		24 h	Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay
human Jurkat cells	Function assay	10-55 μM	24 h	Inhibition of TNFalpha-induced NF-kappaB activation in human Jurkat cells at 10 to 55 uM after 24 hrs by electrophoretic mobility shift assay
human K562 cells	Function assay		24 h	Induction of 67 kDa laminin receptor expression in human K562 cells after 24 hrs by flow cytometry analysis
human HL60 cells	Function assay		24 h	Induction of 67 kDa laminin receptor expression in human HL60 cells after 24 hrs by flow cytometry analysis
human Raji cells	Growth inhibition assay	10 μM	48 h	Growth inhibition against human Raji cells assessed as cell viability at 10 uM after 48 hrs by trypan blue based microscopic analysis in presence of superoxide dismutase
human PC3 cells	Proliferation assay	10-100 μM	48 h	Antiproliferative activity against human PC3 cells at 10 to 100 uM after 48 hrs by hemocytometric cell counting method
human A431 cells	Function assay	100 μM	12 h	Reduction of clustering of GFP-GPI in lipid rafts of human A431 cells at 100 uM after 12 hrs by confocal microscopic analysis
human SKBR3 cells	Function assay	200μM	30 mins	Downregulation of ErbB2 protein expression in human SKBR3 cells in serum free medium at 200 uM after 30 mins by immunofluorescence staining-based confocal microscopic analysis
human 293T cells	Function assay	50 μM	12 h	Inhibition of DYRK1A in human 293T cells assessed as reduction of GLI1 transcription activity at 50 uM after 12 hrs by dual-luciferase reporter gene assay
Click to View More Cell Line Experimental Data

Solubility

In vitro
Batch:

DMSO : 91 mg/mL (198.52 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : 91 mg/mL

Ethanol : 91 mg/mL

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

%

% Tween 80

% ddH₂O

% DMSO

+

%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	458.37	Formula	C₂₂H₁₈O₁₁	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	989-51-5	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent

Mechanism of Action

Targets/IC₅₀/Ki	telomerase DNMT HER2 EGFR FASN
In vitro	(-)-Epigallocatechin gallate functions as a powerful antioxidant, preventing oxidative damage in healthy cells, but also as an antiangiogenic and antitumor agent and as a modulator of tumor cell response to chemotherapy. (-)-Epigallocatechin gallate shows multiple anticancer effects, such as anti-proliferation, anti-angiogenesis, transformation prevention of various cancer cells, cancer cell cycle arrest and inhibition of tumor metastasis. (-)-Epigallocatechin gallate exerts multi-anticancer effects through regulating several cancer-related cell signal pathways (regulated the function or the expression of key signal proteins, such as nuclear factor-κB, MAPKs and activator protein-1, EGFR, IGF, COX-2 signaling pathway, and so on.), effecting methylation of cancer genes and combination of ligand with membrane receptors. (-)-Epigallocatechin gallate also shows an immunomodulating effects. Several types of immune cells in both the innate and adaptive immune systems are known to be affected in varying degrees by (-)-Epigallocatechin gallate. Among them, the dramatic effect on T cell functions has been repeatedly demonstrated, including T cell activation, proliferation, differentiation, and production of cytokines. Studies using animal models of autoimmune diseases have reported disease improvement in animals treated with green tea/EGCG. (-)-Epigallocatechin gallate displays anti-infective properties. Antiviral activities of (-)-Epigallocatechin gallate with different modes of action have been demonstrated on diverse families of viruses, such as Retroviridae, Orthomyxoviridae and Flaviviridae and include important human pathogens like human immunodeficiency virus, influenza A virus and the hepatitis C virus.
References	[1] https://pubmed.ncbi.nlm.nih.gov/16510563/ [2] https://pubmed.ncbi.nlm.nih.gov/23835657/ [3] https://pubmed.ncbi.nlm.nih.gov/23072320/ [4] https://pubmed.ncbi.nlm.nih.gov/21827739/ [5] https://pubmed.ncbi.nlm.nih.gov/29329808/ [6] https://pubmed.ncbi.nlm.nih.gov/27106068/

Applications

Methods	Biomarkers	Images	PMID
Western blot	β-catenin / p-AKT / Cyclin D1 p-MAPK / MAPK Notch1 / Notch2		28693189
Growth inhibiton assay	Cell proliferation Cell viability		23525843

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT05758571	Recruiting	Interstitial Pneumonia\|Neoplasms Malignant	Shandong Cancer Hospital and Institute	January 5 2023	Phase 1\|Phase 2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

EGCG ((-)-Epigallocatechin Gallate) Telomerase inhibitor

Chemical Structure

Molecular Weight: 458.37